PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study.
Du XX, Dong YH, Zhu HJ, Fei XC, Gong YM, Xia BB, Wu F, Wang JY, Liu JZ, Fan LC, Wang YQ, Dong L, Zhu YJ, Pan JH, Dong BJ, Xue W.
Du XX, et al.
Asian J Androl. 2023 Mar-Apr;25(2):179-183. doi: 10.4103/aja2022102.
Asian J Androl. 2023.
PMID: 36537376
Free PMC article.